DIADIA0.01%
SPYSPY0.36%
QQQQQQ0.97%
Trending
Top trending tickerGRPNGRPN1.64%
AVAXAVAX1.32%
TEMTEM0.10%
SATLSATL0.92%
DRTSDRTS2.04%
FUBOFUBO2.06%
FIGFIG0.38%
RXTRXT2.97%
TT0.19%
BLZEBLZE0.13%
Top trending tickerGRPNGRPN1.64%
AVAXAVAX1.32%
TEMTEM0.10%
SATLSATL0.92%
DRTSDRTS2.04%
FUBOFUBO2.06%
FIGFIG0.38%
RXTRXT2.97%
TT0.19%
BLZEBLZE0.13%

Feed

News

Sentiment

Fundamentals

Info

homeSymbolQNTMnews
Exchange: NASDAQ·Updated 06:55 PM EDT
QNTM logo

QNTMQuantum BioPharma Ltd

$3.51
$0.15
(4.46%)
Today
Closed $3.51
$0.01
(0.28%)
After Hours
Mkt Cap$22.46M
Vol114,423.00
News
all
press releases
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is […]
Investor Brand Network
News Placeholder
More News
News Placeholder
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal — generating reliable evidence that a new drug, […]
Investor Brand Network
News Placeholder
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the […]
Investor Brand Network
News Placeholder
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray […]
Investor Brand Network
News Placeholder
Why Did QNTM Stock Pop In Pre-Market Today?
The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.
Stocktwits
News Placeholder
Quantum BioPharma Targets MS Progression with Novel Demyelination Therapy in Phase 2 Push
Quantum BioPharma (NASDAQ:QNTM) is taking a meaningful step forward in its clinical ambitions, signing a binding letter of intent with Allucent to advance its lead multiple sclerosis candidate, Lucid-21-302 (Lucid-MS), into a Phase 2 trial. The agreement signals more than operational progress, it reflects a broader push to bring differentiated, next-generation therapies into a market that remains heavily underserved despite decades of innovation.
24-7 Market News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM INVESTOR ALERT: Pomerantz Law Firm...
PR Newswire
News Placeholder
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM CONTACT: INVESTOR ALERT...
PR Newswire
News Placeholder
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM CONTACT: INVESTOR ALERT...
PR Newswire
News Placeholder
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM CONTACT: INVESTOR ALERT...
PR Newswire
<
1
2
...
>
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.